Valo Therapeutics is developing tumor antigen-coated oncolytic viruses as therapeutic vaccines to enhance the immune response against cancer. Their PeptiCRAd technology provides a specific and adaptable platform for treating various cancers, aiming to improve patient outcomes and expand treatment options.
Funding
$25.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer immunotherapies face challenges in effectively targeting tumors and stimulating a robust, lasting immune response, limiting their efficacy across diverse cancer types. Traditional approaches may not adequately address the need for adaptable and personalized therapies that can overcome tumor-induced immune suppression.
Solution
Valo Therapeutics is developing tumor antigen-coated oncolytic viruses as therapeutic vaccines to enhance the immune response against cancer. Their PeptiCRAd technology provides a versatile platform for creating targeted immunotherapies. This approach involves coating oncolytic viruses with disease-specific peptides, which directs the immune system to recognize and attack tumor cells. By leveraging electrostatic interactions and membrane-penetrating peptides, the platform enables rapid creation of multiple vector-based immunotherapies that promise to provide lasting immunity to many different cancer types.
Target Audience
The primary target audience includes oncology researchers and clinicians seeking to improve cancer immunotherapy outcomes, as well as pharmaceutical companies interested in novel therapeutic platforms.
Features
- PeptiCRAd technology: Coating oncolytic viruses with tumor-specific peptides to enhance targeted immune response.
- Rapid adaptability: Platform allows for quick modification and personalization of therapies to address diverse cancer types.
- Enhanced T-cell response: Elicits a strong T-cell driven immune response to destroy targeted tumors.
- Broad vector compatibility: Can deliver antigens through a wide range of vectors, including adenoviruses, enveloped viruses, and bacteria.
- Electrostatic binding: Utilizes electrostatic interactions for efficient and rapid combination of peptides with the viral vector.